


2

AD-A240 332



DTIC  
ELECTE  
SEP 09 1991  
S C D



# PUBLICATION REPORT

Accession For	
DTIC GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Avail and/or	
Dist	Special
AH	20

1583

65/89-90

LYME DISEASE AGENT IN EGYPT?

BY

Richard L. Haberberger, Niel T. Constantine,  
Tom G. Schwan, and James N. Woody

U.S. NAVAL MEDICAL RESEARCH UNIT NO. 3  
(CAIRO, ARAB REPUBLIC OF EGYPT)

FPO NEW YORK 09527

91-10110



91 9 9- 014

## Short Report

### Lyme disease agent in Egypt?

Richard L. Haberberger, Jr<sup>1</sup>, Niel T. Constantine<sup>1</sup>, Tom G. Schwan<sup>2</sup> and James N. Woody<sup>1</sup> <sup>1</sup>United States Naval Medical Research Unit No. 3, Cairo, Egypt; <sup>2</sup>Laboratory of Pathobiology, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, Montana, 59840, USA

We here report our findings after evaluating individuals from various geographical locations in Egypt for exposure to *Borrelia burgdorferi*.

Our initial screening of sera collected from high-risk individuals with fever of unknown origin (FUO) or meningitis and of low-risk individuals (routine blood bank donors) as controls revealed several reactive samples. To our surprise, all reactive samples were from routine blood bank donors living in an isolated oasis of Egypt. We therefore extended our investigation by assaying 61 individuals from this location, all of whom were either blood bank donors or patients at a clinic for dermatological disorders including sexually transmitted diseases (STD). In Egypt, dermatologists generally care for patients with STDs.

A commercially available indirect fluorescent antibody (IFA) assay (Lyme-check, Diagnostic Technology, Hauppauge, New York, USA) for determination of antibodies to *B. burgdorferi* was performed on the sera from 145 patients with FUO, STD and meningitis and from routine blood bank donors. Due to the possibility of false positives resulting from prior syphilis infection (MAGNARELLIA *et al.*, 1987), these sera were also tested by the rapid plasma reagin (RPR)

test and the fluorescent treponemal antibody absorption (FTA-ABS) test. All sera positive for Lyme disease by IFA were further characterized by Western blot analysis (BARBOUR *et al.*, 1983) at a dilution of 1:100 with the prototype strain B-31 of *B. burgdorferi*.

Results indicated that none of the 16 meningitis or 68 FUO cases had been exposed to *Borrelia*. Of the 61 individuals from Fayoum, a desert oasis some 80 km south-west of Cairo, 14 (23%) were positive with IFA serum titres ranging from 1:256 to 1:2048 when tested with the Lyme disease agent (Table). Western blot analysis of these sera demonstrated that 8 of the 14 sera had specific reactions to 8-14 protein components of *B. burgdorferi*. Of these Lyme IFA reactive sera, 10 reacted positively to the RPR test; however, all tested were negative by the FTA-ABS test. These RPR-positive sera may represent early stage syphilis, or non-syphilitic disease, but are not likely to be cross-reactions induced by exposure to *B. burgdorferi*, since patients with Lyme disease alone fail to react in the RPR test (HUNTER *et al.*, 1986). However, prior exposure to both *Treponema pallidum* and other *Borrelia* is certainly possible and could explain positive titres to both pathogens. Our data indicate that 8 individuals may have been exposed to *B. burgdorferi* or other species of *Borrelia*. *B. crocidurae* is transmitted by the soft tick *Ornithodoros erraticus* and is widespread in Egypt and other parts of northern Africa (KHALIL *et al.*, 1984). The oasis of Fayoum has a large lake and many potential mammalian and avian hosts inhabit or migrate through the area, where ixodid ticks are also present.

We believe that there is serological evidence suggestive that *Borrelia* infection, and possibly Lyme disease, may be present in this area of Egypt and that further efforts to identify its prevalence, clinical presentation, vectors, animal hosts, and epidemiology are warranted.

This research was supported by the Naval Medical Research and Development Command, NMC, NCR, Bethesda, Maryland, USA, Work Unit No. 3M162770A870.AR.322. The opinions and assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the US Department of the Navy or the naval service at large. We thank Merry E. Schrumph for technical assistance.

#### References

- Barbour, A. G., Bergdorfer, W., Grunwaldt, E. & Steere, A. C. (1983). Antibodies of patients with Lyme disease to components of the *Ixodes dammini* spirochete. *Journal of Clinical Investigation*, 72, 504-515.
- Hunter, E. F., Russell, H., Farshy, C. E., Sampson, J. S. & Larsen, S. A. (1986). Evaluation of sera from patients with Lyme disease in the fluorescent treponemal antibody-absorption test for syphilis. *Sexually Transmitted Diseases*, 13, 232-236.
- Khalil, G. M., Helmy, N., Hoogstraal, H. & El-Said, A. (1984). Seasonal dynamics of *Ornithodoros (Parloestovella) erraticus* (Acari: Ixodidae: Argasidae) and the spirochete *Borrelia crocidurae* in Egypt. *Journal of Medical Entomology*, 21, 536-539.
- Magnarellia, L. A., Anderson, J. F. & Johnson, R. C. (1987). Cross-reactivity in serological tests for Lyme disease and other spirochetal infections. *Journal of Infectious Diseases*, 156, 183-188.

Table. Serological results for 14 patients from Fayoum, Egypt\*

No.	Age	Sex	Group	IFA	RPR	FTA-ABS	Western blot
05	52	M	STD	256	-	-	Strong +
17	39	M	Donor	256	-	-	Strong +
90	28	M	Donor	2048	+	-	Strong +
08	65	M	STD	256	+	-	Moderate +
09	10	F	STD	512	+	-	Moderate +
23	24	M	Donor	512	-	-	Moderate +
28	27	M	Donor	1024	+	-	Moderate +
88	44	M	Donor	256	+	-	Weak +
21	27	M	Donor	2048	+	-	Equivocal
72	24	M	STD	512	-	-	QNS
06	10	M	STD	256	+	-	-
74	45	F	STD	2048	+	QNS	-
79	40	F	STD	256	+	QNS	-
87	30	M	Donor	2048	+	-	-

\*Abbreviations: IFA, indirect fluorescent antibody assay; RPR, Lyme rapid plasma reagin test; FTA-ABS, fluorescent treponemal antibody absorption test; STD, sexually transmitted disease; QNS, quantity not sufficient for analysis; M, male; F, female; +, positive; -, negative.

REPORT DOCUMENTATION PAGE

1a. REPORT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>		1b. RESTRICTIVE MARKINGS	
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; Distribution is unlimited.	
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			
4. PERFORMING ORGANIZATION REPORT NUMBER(S)  65/89-90		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
6a. NAME OF PERFORMING ORGANIZATION U.S. Naval Medical Research Unit No. 7	6b. OFFICE SYMBOL (If applicable) NAVMEDRSCHU THREE	7a. NAME OF MONITORING ORGANIZATION	
6c. ADDRESS (City, State, and ZIP Code) PSC 452, Box 5000 FPO, AE 09835-0007		7b. ADDRESS (City, State, and ZIP Code)	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION Naval Medical Research and Development Command	8b. OFFICE SYMBOL (If applicable) NAVMEDRSCH DEVCOM	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER	
8c. ADDRESS (City, State, and ZIP Code) National Naval Medical Center Building 1, Tower 12 Bethesda, MD 20889-5044		10. SOURCE OF FUNDING NUMBERS	
		PROGRAM ELEMENT NO. 62770A	PROJECT NO. 3M1627- 70A870
		TASK NO. AR	WORK UNIT ACCESSION NO.
11. TITLE (include Security Classification) Lyme Disease Agent in Egypt? (UNCLASSIFIED).			
12. PERSONAL AUTHOR(S) Haberberger, Richard L., Constantine, Niel T., Schwan, Tom G., and Woody, James N.			
13a. TYPE OF REPORT	13b. TIME COVERED FROM _____ TO _____	14. DATE OF REPORT (Year, Month, Day) 1989, February, 20	15. PAGE COUNT 1
16. SUPPLEMENTARY NOTATION Published in: Trans. R. Soc. Trop. Med. Hyg., 83:556, 1989; Acc. 1583.			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	Lyme disease; <u>Borrelia</u> spp.; <u>Treponema pallidum</u> ; Patients; Fayoum, Egypt.	
19. ABSTRACT (Continue on reverse if necessary and identify by block number)  As per attached.  • Laboratory of Pathobiology, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, Hamilton, Montana.			

**BEST  
AVAILABLE COPY**

20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>	
22a. NAME OF RESPONSIBLE INDIVIDUAL Research Publications Branch		22b. TELEPHONE (Include Area Code) 202-284-1381	22c. OFFICE SYMBOL R.P.B.